These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 35511749)
1. A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. Fernández-Rodríguez J; Creus-Bachiller E; Zhang X; Martínez-Iniesta M; Ortega-Bertran S; Guha R; Thomas CJ; Wallace MR; Romagosa C; Salazar-Huayna L; Reilly KM; Blakely JO; Serra-Musach J; Pujana MA; Serra E; Villanueva A; Ferrer M; Lázaro C Mol Cancer Ther; 2022 Jul; 21(7):1246-1258. PubMed ID: 35511749 [TBL] [Abstract][Full Text] [Related]
2. Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient-derived orthotopic xenografts, cell lines and tumor entities. Creus-Bachiller E; Fernández-Rodríguez J; Magallón-Lorenz M; Ortega-Bertran S; Navas-Rutete S; Romagosa C; Silva TM; Pané M; Estival A; Perez Sidelnikova D; Morell M; Mazuelas H; Carrió M; Lausová T; Reuss D; Gel B; Villanueva A; Serra E; Lázaro C Mol Oncol; 2024 Apr; 18(4):895-917. PubMed ID: 37798904 [TBL] [Abstract][Full Text] [Related]
3. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165 [TBL] [Abstract][Full Text] [Related]
4. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448 [TBL] [Abstract][Full Text] [Related]
9. Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine. Castellsagué J; Gel B; Fernández-Rodríguez J; Llatjós R; Blanco I; Benavente Y; Pérez-Sidelnikova D; García-Del Muro J; Viñals JM; Vidal A; Valdés-Mas R; Terribas E; López-Doriga A; Pujana MA; Capellá G; Puente XS; Serra E; Villanueva A; Lázaro C EMBO Mol Med; 2015 May; 7(5):608-27. PubMed ID: 25810463 [TBL] [Abstract][Full Text] [Related]
10. Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. Larsson AT; Bhatia H; Calizo A; Pollard K; Zhang X; Conniff E; Tibbitts JF; Rono E; Cummins K; Osum SH; Williams KB; Crampton AL; Jubenville T; Schefer D; Yang K; Lyu Y; Pino JC; Bade J; Gross JM; Lisok A; Dehner CA; Chrisinger JSA; He K; Gosline SJC; Pratilas CA; Largaespada DA; Wood DK; Hirbe AC Neuro Oncol; 2023 Nov; 25(11):2044-2057. PubMed ID: 37246765 [TBL] [Abstract][Full Text] [Related]
11. Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors. Peacock JD; Cherba D; Kampfschulte K; Smith MK; Monks NR; Webb CP; Steensma M J Transl Med; 2013 Sep; 11():213. PubMed ID: 24040940 [TBL] [Abstract][Full Text] [Related]
12. RRM2 as a novel prognostic and therapeutic target of NF1-associated MPNST. Chung MH; Aimaier R; Yu Q; Li H; Li Y; Wei C; Gu Y; Wang W; Guo Z; Long M; Li Q; Wang Z Cell Oncol (Dordr); 2023 Oct; 46(5):1399-1413. PubMed ID: 37086345 [TBL] [Abstract][Full Text] [Related]
14. Combined Targeting of AKT and mTOR Inhibits Proliferation of Human NF1-Associated Malignant Peripheral Nerve Sheath Tumour Cells In Vitro but not in a Xenograft Mouse Model In Vivo. Schulte A; Ewald F; Spyra M; Smit DJ; Jiang W; Salamon J; Jücker M; Mautner VF Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102484 [TBL] [Abstract][Full Text] [Related]
15. Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors. Amirnasr A; Verdijk RM; van Kuijk PF; Taal W; Sleijfer S; Wiemer EAC PLoS One; 2017; 12(8):e0183155. PubMed ID: 28813519 [TBL] [Abstract][Full Text] [Related]
17. Chromosomal translocations inactivating CDKN2A support a single path for malignant peripheral nerve sheath tumor initiation. Magallón-Lorenz M; Fernández-Rodríguez J; Terribas E; Creus-Batchiller E; Romagosa C; Estival A; Perez Sidelnikova D; Salvador H; Villanueva A; Blanco I; Carrió M; Lázaro C; Serra E; Gel B Hum Genet; 2021 Aug; 140(8):1241-1252. PubMed ID: 34059954 [TBL] [Abstract][Full Text] [Related]
18. Integrating analysis of proteome profile and drug screening identifies therapeutic potential of MET pathway for the treatment of malignant peripheral nerve sheath tumor. Tsuchiya R; Yoshimatsu Y; Noguchi R; Sin Y; Ono T; Akiyama T; Kosako H; Yoshida A; Ohtori S; Kawai A; Kondo T Expert Rev Proteomics; 2023; 20(4-6):109-119. PubMed ID: 37229542 [TBL] [Abstract][Full Text] [Related]
19. Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors. Chau V; Lim SK; Mo W; Liu C; Patel AJ; McKay RM; Wei S; Posner BA; De Brabander JK; Williams NS; Parada LF; Le LQ Cancer Res; 2014 Jan; 74(2):586-97. PubMed ID: 24285727 [TBL] [Abstract][Full Text] [Related]
20. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Lopez G; Torres K; Liu J; Hernandez B; Young E; Belousov R; Bolshakov S; Lazar AJ; Slopis JM; McCutcheon IE; McConkey D; Lev D Cancer Res; 2011 Jan; 71(1):185-96. PubMed ID: 21084276 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]